TL;DR
IGF-1 LR3 is a laboratory-modified copy of insulin-like growth factor 1, the hormone your liver makes in response to growth hormone. Two changes to the molecule keep it away from the binding proteins that normally hold IGF-1 in check, so more of it stays active for longer.
- Benefits: real in a dish, unproven in people. A 2026 review in Frontiers in Endocrinology puts IGF-1 LR3 in its lowest evidence tier, reserved for compounds with no peer-reviewed human studies at all. The muscle-building story comes from rat cells and rodents in the early 1990s.
- Side effects: judged by the hormone it copies. The approved IGF-1 drug carries label warnings for severe low blood sugar, allergic reactions, raised pressure around the brain, tonsil enlargement, hip and spine problems in children, and it is contraindicated in anyone with cancer or a history of it.
- Status: not FDA approved, and not a compounding peptide. IGF-1 is 70 amino acids. Anything over 40 is a protein under federal rules, so it is regulated as a biologic, and biologics cannot use the pharmacy compounding pathways that six peptides got in October 2026. It is also prohibited in sport at all times.
This PeptIQ.io guide was updated on November 10, 2026 from PubMed, FDA, HHS and WADA documents. It contains no dosing information.
Talk to a licensed clinician before using IGF-1 LR3 or anything sold under that name.
What Is IGF-1 LR3?
IGF-1 LR3 stands for Long [Arg3] insulin-like growth factor 1. Start with the hormone it copies. IGF-1 is a chain of 70 amino acids your liver releases when growth hormone tells it to, and it carries out much of what people credit to growth hormone itself: tissue growth, repair and cell survival. The approved drug version, mecasermin, is described in its label as having a sequence "identical to that of endogenous human IGF-1."
IGF-1 LR3 is that chain with two edits, made by an Australian research group in 1992:
- Arginine replaces glutamic acid at position 3. That is the "R3" part.
- A 13-residue extension is added to the front of the chain. That is the "Long" part.
Neither change was aimed at making a better medicine. The published purpose was to build reagents — the 1992 paper calls the analogs "very useful reagents in the investigation of IGF-1 action." They were engineered for cell culture work, where IGF binding proteins secreted by the cells soak up ordinary IGF-1 and blunt the experiment.
The edits work by reducing how tightly the molecule sticks to IGF binding proteins. In the original experiments, the analogs bound a binding protein very poorly and actually bound the receptor slightly less well than native IGF-1 — yet they were more potent in cells. The researchers concluded that escaping the binding proteins, not grabbing the receptor harder, explained the extra potency.
That detail matters for how claims about IGF-1 LR3 should be read. The molecule is not a stronger key. It is the same key, carried past the doorman.
How It Is Supposed to Work
Once it reaches the IGF-1 receptor, IGF-1 LR3 is assumed to do what IGF-1 does. The 2026 Frontiers in Endocrinology review describes the two downstream routes:
- PI3K–Akt, which influences protein synthesis and cell survival
- MAPK/ERK, which influences cell-cycle progression and proliferation
The review is careful about the word "assumed." It notes that because IGF-1 LR3 engages the same receptor, it is "generally presumed to elicit comparable downstream signalling, although its altered binding characteristics may influence the magnitude or temporal dynamics of pathway activation."
Those same pathways are the reason IGF-1 biology is studied so heavily in cancer research. The anabolic story and the proliferation story are the same story, read in two directions.
The insulin connection is also structural, not incidental. IGF-1 and insulin are related molecules whose receptors overlap, which is why the approved IGF-1 drug is labeled as having "insulin-like hypoglycemic effects."
What the Evidence Actually Shows
Here is the full published human record for IGF-1 LR3, as of November 10, 2026: there isn't one.
The 2026 narrative review in Frontiers in Endocrinology set out to map performance-enhancing peptides that act on the growth hormone and IGF-1 axis, sorting each into evidence tiers from "randomized controlled trial evidence within an approved clinical indication" down to tier D, meaning "no peer-reviewed human studies, with claims resting on preclinical extrapolation and grey-literature user narratives."
IGF-1 LR3 is tier D. Its row in the review's table reads, for route of administration, half-life, benefits and side effects alike: no peer-reviewed human studies. The review's own summary is blunt — claims about IGF-1 analogs "rest on extrapolation rather than direct human data" and clinicians "should treat exposure to these compounds as evidence-poor."
So what does exist?
Cell studies (1992). In rat myoblast cultures, the analogs were more potent than native IGF-1 at stimulating protein synthesis and DNA synthesis and at blocking protein breakdown. In chicken embryo fibroblasts — a cell line that does not release detectable binding proteins into the surrounding fluid — Long [Arg3]-IGF-1 was less potent than IGF-1. That is the clearest demonstration that the advantage is about binding proteins, and that it disappears when they are absent.
Rodent studies (1992). Rats made catabolic with a steroid were given IGF-1 or its variants by implanted pump. The variants, including LR3, were roughly 2.5 times as potent as IGF-1 at restoring body weight and nitrogen retention. The authors noted the LR3 result was "particularly striking because this peptide binds 3-fold less well than IGF-1 to the type 1 IGF receptor." This is a study of reversing steroid-induced wasting in rats, not of building muscle in a healthy adult.
The closest human reality check. There is no trial of IGF-1 LR3 in people, but there are trials of IGF-1 itself. In a 24-week open-label study of 15 adults with myotonic dystrophy type 1, IGF-1 given with its binding protein increased lean body mass by 1.95 kg — with no significant change in muscle strength or functional outcomes. Three participants had mild transient low blood sugar and one had transient swelling of the optic disc. The 2026 review cites this as evidence that "anabolic signalling and body recomposition do not necessarily translate into clinically meaningful physical performance gains."
That is the honest summary: the mechanism is real, the rodent anabolism is real, and the leap to "it builds muscle in humans" has never been tested.
Safety: What Is Known and What Is Assumed
Because IGF-1 LR3 has never been studied in people, its risk profile is inferred from the hormone it copies. The label for mecasermin, the approved IGF-1 drug, is the most concrete document available. It warns about:
- Severe low blood sugar, including hypoglycemic seizures. The label instructs that it be given close to a meal or snack because of its insulin-like effects.
- Hypersensitivity and allergic reactions, including anaphylaxis requiring hospitalization.
- Raised pressure inside the skull, with eye examinations recommended at the start of treatment and periodically after.
- Tonsil and adenoid enlargement, with periodic examination advised.
- Slipped capital femoral epiphysis and worsening scoliosis in growing children.
- Malignant neoplasia. The drug is contraindicated in patients with cancer or a history of cancer, and treatment is to be stopped if evidence of malignancy develops.
The 2026 review flags the same two domains for off-label IGF-1 analog use. First, reports of symptoms suggestive of low blood sugar, which it calls "biologically plausible given receptor cross-talk within the insulin/IGF axis." Second, long-term cancer risk, which it frames as "theoretical but clinically relevant" in the absence of long-term safety data.
The underlying epidemiology is worth stating precisely, because it is often overstated in both directions. In a UK Biobank analysis of 412,645 people followed for a median of 7.2 years, higher circulating IGF-1 was modestly associated with overall cancer risk (hazard ratio 1.03 per 5 nmol/L in both men and women), with positive associations for breast, prostate, colorectal, melanoma, kidney and thyroid cancers and inverse associations for lung, ovarian, head and neck, and liver cancers. A Mendelian randomization study using 416 genetic variants found support for a causal link with colorectal cancer, and called the evidence for prostate, breast and other cancers "inconclusive or no evidence."
Those studies measure naturally varying hormone levels over years. They do not measure injected analogs, and they cannot tell you what a short course does. They are the reason the concern is taken seriously, not proof of harm.
One more risk is specific to how this compound is sold. In 2010, doping researchers in Cologne analyzed a vial from the black market and identified Long-R3-IGF-1 carrying a His-tag, a handle added during manufacture to make laboratory purification easier. Their conclusion: the effects of His-tagged Long-R3-IGF-1 in humans "have not been elucidated or described," and the product "may rather be a by-product from biochemical studies than synthesized for injection purposes."
Is IGF-1 LR3 Legal? Status in 2026
IGF-1 LR3 is not approved by FDA for any use. The only approved IGF-1 product is mecasermin (INCRELEX), indicated for growth failure in children two years and older with severe primary IGF-1 deficiency, or with a growth hormone gene deletion who have developed neutralizing antibodies to growth hormone. Its label adds that it "is not a substitute to GH for approved GH indications." Nothing about that approval extends to a modified analog used for body composition.
The more interesting question in 2026 is why IGF-1 LR3 was left out of the compounding policy that changed the picture for other peptides.
On October 30, 2026, HHS published an interim enforcement discretion policy for compounding under section 503A using certain peptide bulk substances. Appendix A lists six: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. IGF-1 LR3 is not there. It is also absent from FDA's Category 2 list of bulk substances that may present significant safety risks, where many research peptides appear.
The reason is size, not safety. Under 21 CFR 600.3(h)(6), "a protein is any alpha amino acid polymer with a specific, defined sequence that is greater than 40 amino acids in size." IGF-1 is 70 amino acids; the LR3 version is longer still. That puts it on the protein side of the line, which makes it a biological product regulated under section 351 of the Public Health Service Act rather than a peptide drug substance.
FDA's guidance on biological products states the consequence directly: "for purposes of sections 503A and 503B, a drug does not include any biological product that is subject to licensure under section 351 of the PHS Act. Accordingly, such biological products are not eligible for the exemptions for compounded drugs under sections 503A and 503B." In plain terms, there is no compounding route to a legal IGF-1 analog the way there now is for a short peptide like BPC-157. A product would need its own license.
That distinction is easy to miss when a telehealth site describes IGF-1 LR3 as "physician-prescribed" and shipped by a compounding pharmacy. IGF1LR3.com, a brand site in the meds.you portfolio, currently lists IGF-1 LR3 therapy as in development with a waitlist, while describing benefits including lean muscle growth and "results in 2-4 weeks." Compare marketing language like that against what the research above actually establishes, and ask any prescriber which approved product, if any, you would be receiving. For context on how peptides reach patients in general, meds.you is the parent portfolio site, and our guide on how to vet a peptide source covers the documentation to ask for.
In sport, the answer is simple. The WADA 2026 Prohibited List, in force since January 1, 2026, names "insulin-like growth factor 1 (IGF-1, mecasermin) and its analogues" in class S2, prohibited at all times, in and out of competition. Everything in S2 is a non-specified substance, which means there is no reduced-sanction path for an accidental positive. An analog designed to resist binding proteins is squarely within "and its analogues."
Questions to Raise With a Clinician
If you are considering IGF-1 LR3, or already using it, these are worth asking out loud:
- What approved product, if any, is this? If the answer involves compounding, ask how that squares with IGF-1 being regulated as a biologic.
- What is my personal and family cancer history? The approved IGF-1 drug is contraindicated in people with cancer or a history of it. That contraindication exists for a reason that does not disappear with an analog.
- How would we recognize low blood sugar, and what should I do if it happens away from help? This is the most consistently reported acute concern across IGF-1 analog use.
- What baseline labs make sense, including fasting glucose or HbA1c? The 2026 review recommends these "regardless of compound class."
- What am I already taking? The same review stresses that symptoms in people using performance peptides are often confounded by other substances used alongside them, and should not be pinned on one compound.
- If I have symptoms, who do I report them to? Suspected reactions can be reported to FDA MedWatch.
- Am I subject to drug testing? Students, service members and competitive athletes should confirm before, not after.
How PeptIQ.io Helps
PeptIQ.io's Peptide Claim Auditor takes a link to an Instagram, TikTok, X or Reddit post and checks each peptide claim against published research. It is useful on posts that present IGF-1 LR3 results as established, since the underlying literature is rodent and cell work. The COA checker and the guide to reading a certificate of analysis explain what a lab report does and does not prove — which matters more than usual here, given that a documented black-market sample turned out to be a tagged laboratory construct. If you and your clinician decide on a treatment, the PeptIQ app keeps injections, labs and symptoms on one timeline you can share, and PeptIQ AI answers questions against your own log rather than a forum thread.
Talk to a Licensed Clinician
Talk to a licensed clinician before using IGF-1 LR3. If your goal is muscle or recovery, the conversation worth having is which approaches have human evidence behind them — and this one does not. If you are already using it, tell your clinician, because low blood sugar, vision changes and new lumps are all things they would want to hear about early rather than late. Bring the product, its label and any certificate of analysis with you.
Frequently Asked Questions
Q: What is IGF-1 LR3?
A: IGF-1 LR3 is Long [Arg3] insulin-like growth factor 1, a laboratory-modified version of the IGF-1 hormone. Arginine replaces glutamic acid at position 3 and a 13-residue extension is added to the front, which makes it bind far less tightly to IGF binding proteins. It was created in 1992 as a research reagent, not as a medicine.
Q: Does IGF-1 LR3 build muscle?
A: In rat muscle cells and in steroid-treated rats, yes. In people, it has never been tested. A 2026 review in Frontiers in Endocrinology places it in the tier for compounds with no peer-reviewed human studies. The closest human data, using IGF-1 itself in a muscle disease, raised lean mass but did not improve strength or function.
Q: What are the side effects of IGF-1 LR3?
A: None are documented in published human studies, because there are none. The approved IGF-1 drug's label warns about severe low blood sugar and seizures, allergic reactions including anaphylaxis, raised pressure around the brain, tonsil enlargement, and hip and spine problems in children, and it is contraindicated in people with cancer or a history of cancer.
Q: Is IGF-1 LR3 FDA approved?
A: No. The only approved IGF-1 product is mecasermin (INCRELEX), for children with severe primary IGF-1 deficiency or a growth hormone gene deletion with neutralizing antibodies. IGF-1 LR3 has no approval for any indication.
Q: Is IGF-1 LR3 on the October 2026 HHS peptide list?
A: No. Appendix A of the HHS interim compounding policy names BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. IGF-1 at 70 amino acids exceeds the 40-amino-acid threshold in 21 CFR 600.3(h)(6), so it is regulated as a biologic, and FDA guidance states biologics are not eligible for the 503A or 503B compounding exemptions.
Q: Is IGF-1 LR3 banned in sport?
A: Yes. The WADA 2026 Prohibited List bans insulin-like growth factor 1 and its analogues under class S2, at all times, in and out of competition. Substances in S2 are non-specified, so there is no reduced-sanction category for them.
Q: Is IGF-1 LR3 the same as IGF-1?
A: No. It is IGF-1 with two structural changes that reduce binding-protein capture. In the original work the analog bound the IGF-1 receptor about three times less well than native IGF-1, yet acted more powerfully in cells that secrete binding proteins — and less powerfully in cells that do not.
Related Guides
Sources
- Dominikowski A, et al. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis. Front Endocrinol. 2026. PubMed 42395176
- King R, et al. Production and characterization of recombinant IGF-1 and potent analogues with Gly or Arg substituted for Glu3. J Mol Endocrinol. 1992. PubMed 1311930
- Francis GL, et al. Novel recombinant fusion protein analogues of IGF-1 indicate the relative importance of IGF-binding protein and receptor binding for enhanced biological potency. J Mol Endocrinol. 1992. PubMed 1378742
- Tomas FM, et al. IGF-1 and especially IGF-1 variants are anabolic in dexamethasone-treated rats. Biochem J. 1992. PubMed 1371669
- Heatwole CR, et al. Open-label trial of rhIGF-1/rhIGFBP-3 in myotonic dystrophy type 1. Arch Neurol. 2011. PubMed 20837825
- Kohler M, et al. Detection of His-tagged Long-R3-IGF-1 in a black market product. Growth Horm IGF Res. 2010. PubMed 20675162
- Qian F, Huo D. Circulating IGF-1 and risk of total and 19 site-specific cancers: UK Biobank. Cancer Epidemiol Biomarkers Prev. 2020. PubMed 32856611
- Larsson SC, et al. IGF-1 and site-specific cancers: a Mendelian randomization study. Cancer Med. 2020. PubMed 32717139
- INCRELEX (mecasermin) injection prescribing information, Eton Pharmaceuticals. DailyMed, label revised May 2025
- 21 CFR 600.3(h)(6), definition of a protein
- FDA. Mixing, Diluting, or Repackaging Biological Products Outside the Scope of an Approved Biologics License Application, guidance for industry, January 2018
- HHS. Enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances, Federal Register, October 30, 2026, Appendix A
- FDA. Certain bulk drug substances for use in compounding that may present significant safety risks, content current as of April 22, 2026
- WADA. 2026 Prohibited List, class S2.3, in force January 1, 2026
- ClinicalTrials.gov: searches for IGF-1 LR3, LR3-IGF-I and Long R3 IGF returned no registered studies. Checked November 10, 2026.
This article is educational content from PeptIQ.io. It is not medical advice. Talk with a licensed clinician before starting, stopping, or changing any peptide, medication, or injection practice.
For clinics: running peptide or GLP-1 programs for patients? See PeptIQ.io for providers: protocol templates, a patient app, and adherence tracking in one console.